Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Immunocore Holdings plcNASDAQ: IMCR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $12.95M rose 157.8% year over year, ahead of the +28.8% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -20.5% a year.
Context
- Net income amounted to 8.9% of revenue in FY2025, down 11.7 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of $2.53M (+109.6%) for the fiscal year ending Dec 2026, a step up from the -48.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $12.95M+143.1% QoQ
- Last fiscal yearDec 2025
- -$26.42M-48.3% YoY
- LTMMar 2026
- -$27.59M+28.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +157.8% | +105.0% | -52.8 pp |
| 1 year | -48.3% | +109.6% | +157.9 pp |
| 3-year CAGR | -20.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
Mixed currencies · from the cash flow
- Latest · FY2025
- (26.42M) USD
- Year-over-year change
- +48.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.42M) | +48.3% |
| FY2024 | 2024-12-31 | (51.09M) | — |
| FY2023 | 2023-12-31 | (34.32M) | +34.7% |
| FY2022 | 2022-12-31 | (52.54M) | +70.8% |
| FY2021 | 2021-12-31 | (180.03M) | — |
Net Income vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +28.8% is the 7th highest of 10, against a peer median of +47.3%.
- Net income amounts to 7.2% of revenue for IMCR, versus a peer median of 461.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.71B EUR | +348.2% | — | 64.7% | |
| LTM Sep 2026 | $1.11B USD | +218.3% | -5.5% | 607.8% | |
| LTM Jun 2026 | $460M USD | +54.4% | +9.8% | 393.2% | |
| LTM Mar 2026 | €217.14M EUR | +906.0% | — | 582.2% | |
| LTM Mar 2026 | $114.48M USD | +47.3% | +21.7% | 529.7% | |
| LTM Jun 2026 | $71.19M USD | -60.8% | +18.5% | 67.8% | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| FY2025 | A$61.43M AUD | +43.8% | +24.0% | 1218.0% | |
| FY2025 | €49.18M EUR | -0.6% | -5.4% | 1764.5% | |
| LTM Dec 2025 | $35.34M USD | — | — | 48.6% | |
| LTM Mar 2026 | $27.59M USD | +28.8% | -20.5% | 7.2% | |
| Peer median (excluding IMCR) | — | +47.3% | +9.8% | 461.4% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (180.03M) | (52.54M) | (34.32M) | (51.09M) | (26.42M) |
| Depreciation & Amortization | 7.59M | 5.34M | 3.24M | 4.2M | 2.43M |
| Deferred Income Tax | (12.69M) | (3.53M) | 0 | 0 | 11M |
| Stock-Based Compensation | 48.89M | 32.89M | 25.69M | 34.19M | 0 |
| Change in Working Capital | (21.96M) | (24.17M) | 4.58M | 45.13M | (6.92M) |
| Accounts Receivables | (4.86M) | (26.26M) | (14.14M) | (12.35M) | (5.46M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.47M | 4.91M | 2.08M | 7.27M | (1.83M) |
| Other Working Capital | (18.57M) | (2.81M) | 16.64M | 50.21M | 366K |
| Other Non-Cash Items | 15.09M | (7.19M) | 3.14M | (6.38M) | 11.94M |
| Operating Cash Flow | (143.11M) | (49.21M) | 2.33M | 26.06M | (7.97M) |
| Capital Expenditures | (1.39M) | (2.2M) | (4.29M) | (5.17M) | (3.23M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (350M) | (22.32M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 13.39M |
| Other Investing Activities | 106K | 6K | (925.46K) | 44K | 0 |
| Investing Cash Flow | (1.28M) | (2.2M) | (4.29M) | (355.13M) | (12.16M) |
| Debt Repayment | 0 | 0 | 0 | 352.5M | 0 |
| Common Stock Issued | 286.89M | 139.52M | 0 | 6.8M | 9.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 5.93M | 27.18M | (15.42M) | 0 |
| Financing Cash Flow | 288.19M | 145.44M | 27.18M | 343.88M | 9.2M |
| Effect of Forex Changes | 625K | (12.65M) | 6.56M | (1.71M) | 19.81M |
| Net Change in Cash | 144.42M | 81.39M | 31.78M | 13.11M | 8.89M |
| Free Cash Flow | (144.49M) | (51.41M) | (1.97M) | 20.89M | (11.2M) |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.